Angiogenesis in anatomy, activity and information in patients with advanced breast cancer

被引：0
作者：
Pienkowski, Tadeusz [1 ]
机构：
[1] Inst Warszawie, Ctr Onkol, Klin Nowotworow Piersi & Chirurg Rekonstrukcyjnej, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2009年 / 5卷
关键词：
advanced breast cancer; angiogenesis; bevacizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Angiogenesis, the process of new blood vessel formation, is required for tumor growth and metastasis. There is preclinical evidence supporting the role of neoangiogenesis in tumor progression and metastasis. Vascular endothelial growth factor plays the key role in angiogenesis. The inhibition of angiogenesis may be an effective treatment for patients with advanced breast cancer. Bevacizumab, monoclonal antibody targeting vascular endothelial growth factor is active in breast cancer patients. A large randomized Ill phase clinical trails demonstrated a significant benefit in progression free survival and clinical response rate from addition of bevacizumab to paclitaxel or docetaxel for first line treatment of advanced breast cancer. Bevacizumab plus paclitaxel or docetaxel is effective and safe treatment in patients with advanced breast cancer. Other antiangionenic therapies are now under intensive clinical research.
引用
收藏
页码：A22 / A25
页数：4
相关论文
共 13 条
[1]  
Burstein HJ, 2005, BREAST CANCER RES TR, V94, pS6
[2]   A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J].
Cobleigh, MA ;
Langmuir, VK ;
Sledge, GW ;
Miller, KD ;
Haney, L ;
Novotny, WF ;
Reimann, JD ;
Vassel, A .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :117-124
[3]   Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels [J].
Colleoni, M ;
Rocca, A ;
Sandri, MT ;
Zorzino, L ;
Masci, G ;
Nolè, F ;
Peruzzotti, G ;
Robertson, C ;
Orlando, L ;
Cinieri, S ;
de Braud, F ;
Viale, G ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 2002, 13 (01) :73-80
[4]  
MILES D, 2008, P AM SOC CLIN ONC S, V26
[5]   Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].
Miller, Kathy ;
Wang, Molin ;
Gralow, Julie ;
Dickler, Maura ;
Cobleigh, Melody ;
Perez, Edith A. ;
Shenkier, Tamara ;
Cella, David ;
Davidson, Nancy E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676
[6]  
Miller KC, 2005, J CLIN ONCOL, V23, p574S
[7]   Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J].
Miller, KD ;
Chap, LI ;
Holmes, FA ;
Cobleigh, MA ;
Marcom, PK ;
Fehrenbacher, L ;
Dickler, M ;
Overmoyer, BA ;
Reimann, JD ;
Sing, AP ;
Langmuir, V ;
Rugo, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :792-799
[8]  
Rugo H., 2008, P AM SOC CLIN ONCOL, V26
[9]  
Slamon D., 2008, P AM SOC CLIN ONCOL, V26
[10]   Vascular endothelial growth factor in breast cancer: Biologic and therapeutic aspects [J].
Sledge, GW .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :104-110
12